NCT07282457 (PRISM) is a Phase 1, PHASE2 clinical trial of ZM-02 (low dose) in Retinitis Pigmentosa (RP), sponsored by Zhongmou Therapeutics.

Who is sponsoring NCT07282457?

NCT07282457 is sponsored by Zhongmou Therapeutics.

What drugs are being tested in NCT07282457?

Interventions in NCT07282457: ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose), Sham injection.

What condition does NCT07282457 study?

NCT07282457 studies Retinitis Pigmentosa (RP).

Is NCT07282457 still recruiting?

NCT07282457 is currently not yet recruiting. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07282457: PRISM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

Not yet recruiting Phase 1, PHASE2 Last updated 13 April 2026

What this trial tests

Phase 1, PHASE2 trial testing ZM-02 (low dose) in Retinitis Pigmentosa (RP) in 21 participants. Not yet recruiting.

Timeline

25 June 2026

Primary endpoint
25 December 2029

25 December 2031

Quick facts

Lead sponsor	Zhongmou Therapeutics
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	21
Start date	25 June 2026
Primary completion	25 December 2029
Estimated completion	25 December 2031

Drugs / interventions tested

ZM-02 (low dose)
ZM-02 (high dose)
ZM-02 (selected dose)
Sham injection — full drug profile →

Conditions studied

Retinitis Pigmentosa (RP) — all drugs for Retinitis Pigmentosa (RP) →

Sponsor

Zhongmou Therapeutics — full company profile →

Who can join

Adults 6 to 60, any sex, with Retinitis Pigmentosa (RP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1/2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Retinitis Pigmentosa (RP)

Currently open trials in the same condition.

NCT07266584 — Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration · NA · recruiting
NCT07341919 — Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases · Phase 1, PHASE2 · active not recruiting
NCT07348588 — Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases · Phase 1, PHASE2 · active not recruiting

Other Zhongmou Therapeutics trials

Trials by the same sponsor.

NCT07085533 — Natural History Study of Inherited Retinal Diseases · recruiting
NCT06292650 — Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients · EARLY_PHASE1 · recruiting
NCT06066008 — Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07282457 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongmou Therapeutics
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07282457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing